Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus: An open, multicentre, observational study

Clinical Drug Investigation

Volumn 25, Issue 5, 2005, Pages 337-340

  Konrad, Thomas ^a   Lübben, Georg ^a   Franzen, Christine ^a  

^a European RISC Study Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATION; OPEN STUDY; PRIORITY JOURNAL;

EID: 20444413761     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525050-00006     Document Type: Article

References (23)

1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-44
2. Perneger TV, Brancati FL, Whelton PK, et al. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121: 912-8
3. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 23: risk factors for coronary artery disease in non-insulin dependent diabetes. BMJ 1998; 316: 823-8
4. Hypertension in Diabetes Study Group. HDS 2: increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-25
5. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study X: urinary albumin excretion over 3 years in diet-treated type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36: 1021-9
6. Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996; 335: 1636-42
7. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of type 2 diabetes and associated risk factors. Arch Ophthalmol 1998; 116: 297-303
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
9. Ferranini E. Insulin resistance and blood pressure. In: Reaven G. Laws A, editors. Contemporary endocrinology: insulin resistance: the metabolic syndrome X. Totowa (NJ): Humana Press Inc., 1999: 281-308
10. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
11. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive pre-diabetic subjects: implications for preventing coronary heart disease during pre-diabetic state. Circulation 2000; 101: 975-80
12. Martens FMAC, Visseren FLJ, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62 (10): 1463-80
13. Diamant M, Heine RJ, Thiazolidinediones in type II diabetes mellitus: current clinical evidence. Drugs 2003; 63 (13): 1373-405
14. Gilling L, Suwattee P, DeSouza C, et al. Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs 2002; 2 (3): 149-56
15. Füllen S, Schneider F, Haak E, et al. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-6
16. Gerber P, Lübben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med-Res Opin 2003; 19 (6): 532-9
17. Göke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1: 329-36
18. US Department of Health and Human Services. The Seventh Report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. NIH Publication No. 03- 5233; 2003: 1-34
19. Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003; 25 Suppl. B: B4-B31
20. Sutton MSJ, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25 (11): 2058-64
21. Bennett SMA, Agrawal A, Elashat H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415-22
22. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary artery disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 827-38
23. Sung BH, Izzo JL, Dandona P, et al. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34: 83-8